litlas
Log inCreate account

Constantine S. Tam

Active 2004–2026

211
Papers
26,302
Citations
78
h-index
193
i10-index

Citations

Citations per year for Constantine S. Tam1979: 1 citations2005: 2 citations2006: 4 citations2007: 3 citations2008: 8 citations2009: 36 citations2010: 56 citations2011: 32 citations2012: 25 citations2013: 31 citations2014: 38 citations2015: 106 citations2016: 106 citations2017: 181 citations2018: 207 citations2019: 778 citations2020: 1,237 citations2021: 1,450 citations2022: 1,242 citations2023: 931 citations2024: 1,779 citations2025: 887 citations2026: 33 citations1980–2004: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,725 citing papers, 26.9% of this breakdownGermany: 722 citing papers, 7.1% of this breakdownChina: 716 citing papers, 7.1% of this breakdownUnited Kingdom: 666 citing papers, 6.6% of this breakdownItaly: 631 citing papers, 6.2% of this breakdownFrance: 501 citing papers, 5% of this breakdownAustralia: 462 citing papers, 4.6% of this breakdownSpain: 435 citing papers, 4.3% of this breakdownCanada: 287 citing papers, 2.8% of this breakdownSwitzerland: 281 citing papers, 2.8% of this breakdownNetherlands: 266 citing papers, 2.6% of this breakdownSweden: 175 citing papers, 1.7% of this breakdown
0%26.9%Other 22.3%

Institutions

Fields

  • Medicine89%
  • Biochemistry, Genetics and Molecular Biology7.4%
  • Immunology and Microbiology1.9%
  • Chemistry0.4%
  • Engineering0.2%
  • Materials Science0.2%
  • Other0.9%

Topics

  • CAR-T cell therapy research14.8%
  • Chronic Lymphocytic Leukemia Research12.6%
  • Lymphoma Diagnosis and Treatment12.1%
  • Virus-based gene therapy research3.2%
  • Immunodeficiency and Autoimmune Disorders2.9%
  • Chronic Myeloid Leukemia Treatments2.8%
  • Other51.6%

Coauthors

All papers

Open in search
  1. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Authors: Stephen J. Schuster, Michael Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann, Joseph P. McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R. Westin, Isabelle Fleury, Veronika Bachanová, S.R. Foley, P. Joy Ho, Stephan Mielke, John Magenau, Harald Holte, Serafino Pantano, Lida Pacaud, Rakesh Awasthi, Jufen Chu, Özlem Anak, Gilles Salles, Richard T. Maziarz - New England Journal of Medicine 2018 cited by 4,044

  2. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

    Authors: Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, Nina Worel, Joseph P. McGuirk, Harald Holte, Edmund K. Waller, Samantha Jaglowski, Michael Bishop, Lloyd E. Damon, S.R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Murali Janakiram, Jing-Mei Hsu, Koji Izutsu, Marie José Kersten, Monalisa Ghosh, Nina D. Wagner‐Johnston, Koji Kato, Paolo Corradini, Marcela Martínez-Prieto, Xia Han, Ranjan Tiwari, Gilles Salles, Richard T. Maziarz - The Lancet Oncology 2021 cited by 561

  3. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Authors: Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan O’Brien, Constantine S. Tam, Lugui Qiu, Keshu Zhou, Martin Šimkovič, Jiřı́ Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte Yimer, Tommi Salmi, Megan-Der-Yu Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman - New England Journal of Medicine 2022 cited by 457

  4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    Authors: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 cited by 1,562

  5. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    Authors: Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepłuch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen - The Lancet Oncology 2022 cited by 278

  6. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

    Authors: Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech‐Marańda, Nicole Lamanna, Constantine S. Tam, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Bita Fakhri, Chan Y. Cheah, Manish R. Patel, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna Rhodes, Francisco J. Hernandez‐Ilizaliturri, Pier Luigi Zinzani, John F. Seymour, Minna Balbas, Binoj C. Nair, Paolo Abada, Chunxiao Wang, Amy S. Ruppert, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak - New England Journal of Medicine 2023 cited by 217

  7. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    Authors: Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro J. Alencar, Ewa Lech‐Marańda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal Barve, Bryone J. Kuss, Justin Taylor, Omar Abdel‐Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 cited by 454

  8. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

    Authors: Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia - Blood 2022 cited by 238

  9. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

    Authors: Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts - Cancer Discovery 2018 cited by 426

  10. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    Authors: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 cited by 1,617

  11. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

    Authors: Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen O. McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Judith Trotman, Wai‐Yee Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios Α. Dimopoulos - Blood 2020 cited by 448

  12. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Authors: Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach - American Journal of Hematology 2019 cited by 473

  13. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    Authors: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer‐Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam - Journal of Clinical Oncology 2021 cited by 229

  14. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

    Authors: Rachel Thijssen, Luyi Tian, Mary Ann Anderson, Christoffer Flensburg, Andrew Jarratt, Alexandra L. Garnham, Jafar S. Jabbari, Hongke Peng, Thomas E. Lew, Charis E. Teh, Quentin Gouil, Angela Georgiou, Tania Tan, Tirta M. Djajawi, Constantine S. Tam, John F. Seymour, Piers Blombery, Daniel H.D. Gray, Ian J. Majewski, Matthew E. Ritchie, Andrew W. Roberts, David C.S. Huang - Blood 2022 cited by 88

  15. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

    Authors: Piers Blombery, Ella R. Thompson, Thomas E. Lew, Ing Soo Tiong, Rory Bennett, Chan Y. Cheah, Katharine L. Lewis, Sasanka M. Handunnetti, Chloe Pek Sang Tang, Andrew W. Roberts, John F. Seymour, Constantine S. Tam - Blood Advances 2022 cited by 93

  16. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

    Authors: Julie R. McMullen, Esther J. H. Boey, Jenny Y. Y. Ooi, John F. Seymour, Michael J. Keating, Constantine S. Tam - Blood 2014 cited by 401

  17. First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

    Authors: John F. Seymour, Chan Y. Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason C. Paik, Amit Agarwal, Constantine S. Tam - Blood 2023 cited by 66

  18. Genomic profiling for clinical decision making in lymphoid neoplasms

    Authors: Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elı́as Campo, Andrew Davies, Ahmet Doǧan, Jude Fitzgibbon, Steven M. Horwitz, Ari Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverría, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfgang Hiddemann, Won Seog Kim, Rebecca L. King, Young Hyeh Ko, Ann S. LaCasce, Georg Lenz, José I. Martín‐Subero, Miguel Á. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla‐Martínez, Scott J. Rodig, Andreas Rosenwald, Gilles Salles, Jesús F. San Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier Luigi Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott - Blood 2022 cited by 161

  19. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

    Authors: Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Étienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott D. Lunin, F. Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia Kelly, Barry Turnbull, Stephan Stilgenbauer - Blood 2018 cited by 341

  20. CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

    Authors: Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul Shaughnessy, Armin Ghobadi, Michael Bishop, Ana Alfonso Piérola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William B. Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant-Cohen, Richard T. Maziarz, Carlos Bachier - Blood 2022 cited by 53

  21. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

    Authors: Rakesh Awasthi, Lida Pacaud, Edward Waldron, Constantine S. Tam, Ulrich Jäger, Peter Borchmann, Samantha Jaglowski, S.R. Foley, Koen van Besien, Nina D. Wagner‐Johnston, Marie José Kersten, Stephen J. Schuster, Gilles Salles, Richard T. Maziarz, Özlem Anak, Christopher del Corral, Jufen Chu, Irina Gershgorin, Iulian Pruteanu-Malinici, Abhijit Chakraborty, Karen Thudium Mueller, Edmund K. Waller - Blood Advances 2020 cited by 143

  22. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

    Authors: Constantine S. Tam, Judith Trotman, Stephen Opat, Jan A. Burger, Gavin Cull, David Gottlieb, Rosemary Harrup, Patrick B. Johnston, Paula Marlton, Javier Muñoz, John F. Seymour, David Simpson, Alessandra Tedeschi, Rebecca Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane Huang, William Novotny, Lai Wang, Andrew W. Roberts - Blood 2019 cited by 367

  23. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

    Authors: Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine S. Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Éric Ghigo, Ian J. Majewski, David Segal, Sari L. Heitner Enschede, David C.S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts - Blood 2016 cited by 329

  24. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

    Authors: Silvia Bonfiglio, Lesley‐Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi Asl, Aron Skaftason, Anna Gellerbring, Anna Lyander, Francesca Gandini, Gianluca Gaïdano, Livio Trentin, Lisa Bonello, Gianluigi Reda, Csaba Bödör, Niki Stavroyianni, Constantine S. Tam, Roberto Marasca, Francesco Forconi, Panayiotis Panayiotidis, Ingo Ringshausen, Ozren Jakšić, Anna Maria Frustaci, Sunil Iyengar, Marta Coscia, Stephen P. Mulligan, Loïc Ysebaert, Владимир Стругов, Carolina Pavlovsky, Renata Walewska, Anders Österborg, Diego Cortese, Pamela Ranghetti, Panagiotis Baliakas, Κώστας Σταματόπουλος, Lydia Scarfò, Richard W. Rosenquist, Paolo Ghia - Blood Advances 2023 cited by 66